Cancer poses a significant concern within the veterinary sector, affecting 6 million pet dogs each year. While advancements in human medicine have yielded sophisticated screening tests enabling early interventions, the landscape in veterinary medicine is still evolving.

Accurate screening holds the promise of vastly improving dogs’ quality of life and enriching the bond they share with their owners. Sadly, many cases are only diagnosed when symptoms become distressingly evident.

At OMICA, we adhere to the ONE HEALTH philosophy, prioritising the integration of the latest technology into the veterinary market to make early diagnosis in dogs possible.

Cancer poses a significant concern within the veterinary sector, affecting 6 million pet dogs each year. While advancements in human medicine have yielded sophisticated screening tests enabling early interventions, the landscape in veterinary medicine is still evolving.

Accurate screening holds the promise of vastly improving dogs’ quality of life and enriching the bond they share with their owners. Sadly, many cases are only diagnosed when symptoms become distressingly evident.

At OMICA, we adhere to the ONE HEALTH philosophy, prioritising the integration of the latest technology into the veterinary market to make early diagnosis in dogs possible.

.

KNOW MORE

In oncology, early detection is key.

Not only enhances treatment outcome but also

improves the quality of life for your patients.

REQUEST INFORMATION

In oncology, early detection is key.

Not only enhances treatment outcome but also

improves the quality of life for your patients.

REQUEST INFORMATION

OncoCan is an effective and affordable blood test tailored for dogs at increased risk of cancer due to age, genetics, or breed-specific factors.

This test has successfully detected a wide range of systemic cancers with high accuracy, identifying conditions such as lymphoma, hemangiosarcoma, mastocytoma, and osteosarcoma with a 91% detection rate and 85% specificity. It also detects other less frequent tumors like melanoma, histiocytic sarcoma, and mammary tumors.

Lymphoma, the most prevalent type of canine cancer, accounts for approximately one-third of all canine cancer cases. It also shows the most favorable outcomes when detected early with the OncoCan test.

By transforming the challenges of early diagnosis into proactive discussions between veterinarians and pet owners, the OncoCan test becomes an integral part of regular wellness routines, enhancing preventive care and overall canine health.

At the heart of our mission is strengthening the bond between pets and their owners. We aim to provide tools that foster hope and knowledge in pet care, empowering families to enjoy more meaningful moments together.

KNOW MORE

OncoCan is an effective and affordable blood test tailored for dogs at increased risk of cancer due to age, genetics, or breed-specific factors.

This test has successfully detected a wide range of systemic cancers with high accuracy, identifying conditions such as lymphoma, hemangiosarcoma, mastocytoma, and osteosarcoma with a 91% detection rate and 85% specificity. It also detects other less frequent tumors like melanoma, histiocytic sarcoma, and mammary tumors.

Lymphoma, the most prevalent type of canine cancer, accounts for approximately one-third of all canine cancer cases. It also shows the most favorable outcomes when detected early with the OncoCan test.

By transforming the challenges of early diagnosis into proactive discussions between veterinarians and pet owners, the OncoCan test becomes an integral part of regular wellness routines, enhancing preventive care and overall canine health.

At the heart of our mission is strengthening the bond between pets and their owners. We aim to provide tools that foster hope and knowledge in pet care, empowering families to enjoy more meaningful moments together.

.

KNOW MORE

How Doest it Work?

REQUEST INFORMATION

How Doest it Work?

REQUEST INFORMATION

OncoCan is a blood test designed to detect malignant tumors by identifying circulating cell-free tumor DNA (ctDNA) in the bloodstream.

As a tumor grows, the concentration of circulating tumor DNA (ctDNA) in the bloodstream also increases. The OncoCan test is designed to detect these variations in ctDNA concentration as they occur.
The test is also able to identify whether if these molecules actually originate from the tumor, or from naturally-ocurring processes, such as inflammation

.

KNOW MORE

OncoCan is a blood test designed to detect malignant tumors by identifying circulating cell-free tumor DNA (ctDNA) in the bloodstream.

As a tumor grows, the concentration of circulating tumor DNA (ctDNA) in the bloodstream also increases. The OncoCan test is designed to detect these variations in ctDNA concentration as they occur.
The test is also able to identify whether if these molecules actually originate from the tumor, or from naturally-ocurring processes, such as inflammation

.

KNOW MORE

Customer testimonials



“As a veterinary oncologist, I am convinced that Oncotest will transform our care practice. This liquid biopsy test represents a major advancement, offering significant benefits for our canine patients, their families, and for us, the professionals dedicated to their care.”